BPC-157 may not be appropriate when: Imaging or specialist review has not yet been completed for a suspected structural injury There are acute red flag features (severe weakness, fever, rapid unexplained swelling, neurological changes, unexplained weight loss) The patient has active cancer or a history of certain cancers where angiogenic peptides require careful risk assessment The goal is rapid results without addressing underlying load, rehabilitation, or lifestyle drivers A peptide should not be used to delay evaluation that is clearly warranted
Women who use BPC-157 for gut health consistently report some of the best early results across any demographic we see
Overall effects GLP1-RA treatment is associated with a 37% increase in gallbladder or biliary diseases compared with placebo
Life-long compliance to GLP-1s is the key, and high-touch support is required to educate patients, titrate dosing appropriately, guide people through the side effects, and help them stick with the weekly dosing regimen
How does Durham Peptides' BPC-157 compare to other suppliers on stability